All In Biotech

Investigational drug · Phase 3

Ezabenlimab

Also called: BI 754091

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Cancer, Neoplasm Metastasis, Advanced Tumors.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

27

Any phase or sponsor naming "Ezabenlimab"

First trial start

2019

Mar 19, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Ezabenlimab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Cancer
  • Neoplasm Metastasis
  • Advanced Tumors
  • Metastatic Solid Tumors

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Ezabenlimab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 14 on PubMed

Also in development for Advanced Cancer

  • ObrixtamigBI 764532Phase 36 trials

    Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology

  • ALK201Phase 22 trials

    Shanghai Allink Biotherapeutics Co., Ltd. · NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Cancer, Advanced Solid Tumors

  • CVM-1118TRX-818Phase 22 trials

    TaiRx, Inc. · Hepatocellular Carcinoma, Advanced Cancer, Neuroendocrine Tumors

  • KB707Phase 22 trials

    Krystal Biotech, Inc. · Cancer, Melanoma Stage III, Melanoma Stage IV

  • LY188011Phase 22 trials

    Eli Lilly · Neoplasms, Child, Adolescent

  • Seqker Biosciences, Inc. · Solid Tumors, Advanced Cancer, Recurrent Cancer

  • TST001Phase 22 trials

    Transcenta Therapeutics (Hangzhou) Co., Ltd. · Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer

  • APL-101Phase 21 trial

    Apollomics Inc. · Solid Tumors, Advanced Cancer, Renal Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.